Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications
Graph Chatbot
Chattez avec Graph Search
Posez n’importe quelle question sur les cours, conférences, exercices, recherches, actualités, etc. de l’EPFL ou essayez les exemples de questions ci-dessous.
AVERTISSEMENT : Le chatbot Graph n'est pas programmé pour fournir des réponses explicites ou catégoriques à vos questions. Il transforme plutôt vos questions en demandes API qui sont distribuées aux différents services informatiques officiellement administrés par l'EPFL. Son but est uniquement de collecter et de recommander des références pertinentes à des contenus que vous pouvez explorer pour vous aider à répondre à vos questions.
The goals of tissue engineering include recapitulating specific tissue functions for regenerative medicine and developing in vitro models of human tissues to study human physiology and pathophysiology and for testing and screening drugs before expensive cl ...
Head and neck (H&N) cancer patients have a high incidence of second primary tumors in the tracheobronchial tree. Diagnostic autofluorescence endoscopy (DAFE) has shown promising results in the detection of early neoplastic and pre-neoplastic changes in the ...
Tumors consist of cells whose growth and morphological characteristics are markedly different from those of normal cells. Observation of human and animal models argue that tumor development proceeds via a process formally analogous to Darwinian evolution, ...
Recent findings indicate that tumor-associated macrophages are important drivers of tumor angiogenesis. Here, we review the essential role played by Tie2-expressing monocytes (TEM) in this phenomenon. TEMs are present in human blood and tumors and their el ...
Tumor-infiltrating myeloid cells, including tumor-associated macrophages (TAMs), have been implicated in tumor progression. We recently described a lineage of mouse monocytes characterized by expression of the Tie2 angiopoietin receptor and required for th ...
NOVELTY - A formulation comprising one or more components chosen from interleukin (IL)-2 or a derivative thereof coupled to a transport protein, a monoclonal anti-IL-2 antibody, a cancer vaccine based on specific antigens of tumors or tumor growth factors ...
